Claudin-6 (CLDN6) and Folate Receptor Alpha (FRα) Targeted Antibody-Drug Conjugates: Bypassing Platinum Resistance and Tumor Heterogeneity in High-Grade Serous Ovarian Carcinoma
DOI:
https://doi.org/10.54133/ajms.v11i2.3258Keywords:
High-Grade Serous Ovarian Carcinoma, Folate Receptor Alpha, Mirvetuximab, Soravtansine, Platinum ResistanceAbstract
High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecologic malignancy, and predicting its outcomes is complicated by two interlinked adversaries: the near-inevitable development of platinum resistance that depletes the most successful drug class against the disease and a profound molecular and antigenic heterogeneity that defies targeted therapy. Antibody-drug conjugates (ADCs) directed against tumor-associated antigens offer a strategically attractive answer to both because they kill through a cytotoxic mechanism of microtubule disruption by a delivered payload that is wholly independent of the DNA-repair and drug-handling pathways that confer platinum resistance and because the bystander effect of their membrane-permeable payloads can reach antigen-negative cells within a heterogeneous tumor. This review examines two complementary antigens that researchers are pursuing in HGSOC. Folate receptor alpha (FRα), overexpressed in the great majority of these tumors, is the target of mirvetuximab soravtansine, the first agent of any class to demonstrate an overall-survival benefit in platinum-resistant ovarian cancer and the first ADC approved for this disease. Claudin-6 (CLDN6), an oncofetal tight-junction protein essentially absent from normal adult tissue and expressed in roughly half of HGSOC, is the target of the first-in-class ADC TORL-1-23, which has shown encouraging response rates in platinum-resistant disease in early-phase testing. We detail the biology and resistance mechanisms of HGSOC; the rationale by which antigen-directed payload delivery bypasses platinum resistance; the design, clinical validation, and pipeline of FRα- and CLDN6-targeted ADCs; the way bystander killing, complementary antigen coverage, and biomarker-guided selection address heterogeneity; the safety; and resistance.
Downloads
References
Grither WR, et al. Rethinking ovarian cancer III: the past decade and future directions. Nat Rev Cancer. 2026:1-20. doi: 10.1038/s41568-026-00916-0. DOI: https://doi.org/10.1038/s41568-026-00916-0
Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4(9):1239-1257. doi: 10.1038/s43018-023-00617-9. DOI: https://doi.org/10.1038/s43018-023-00617-9
Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer. J Clin Oncol. 2019;37(27):2437-2448. doi: 10.1200/JCO.19.00194. DOI: https://doi.org/10.1200/JCO.19.00194
Richardson DL, Eskander RN, O’Malley DM. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol. 2023;9(6). doi: 10.1001/jamaoncol.2023.0197. DOI: https://doi.org/10.1001/jamaoncol.2023.0197
Matulonis UA, Lorusso D, Oaknin A. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol. 2023;41(13):2436-2445. doi: 10.1200/JCO.22.01900. DOI: https://doi.org/10.1200/JCO.22.01900
Kefas J, Flynn M. Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: Rationale, challenges, and novel strategies. Cancer Drug Resist. 2024;7:39. doi: 10.20517/cdr.2024.67. DOI: https://doi.org/10.20517/cdr.2024.67
Chen B, Zheng X, Wu J, Chen G, Yu J, Xu Y, et al. Antibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions. Mol Cancer. 2025;24(1):279. doi: 10.1186/s12943-025-02489-2. DOI: https://doi.org/10.1186/s12943-025-02489-2
Cheng X, Li P, Jiang R, Meng E, Wu H. ADC: A deadly killer of platinum resistant ovarian cancer. J Ovarian Res. 2024;17(1):196. doi: 10.1186/s13048-024-01523-z. DOI: https://doi.org/10.1186/s13048-024-01523-z
Popov D. Diagnostic and Therapeutic Antibodies in Oncology: Mechanisms, Clinical Applications, and Future Directions. Precision Oncology through Cancer Antigens: Diagnostic and Therapeutic Antibody Approaches.
An M, Yan J, Liu B, Liu Q. Harnessing the power of CAR-NK cells for solid tumors: challenges, innovations, and future frontiers in immunotherapy. Cancer Commun. 2026;46:0023. doi: 10.34133/cancomm.0023. DOI: https://doi.org/10.34133/cancomm.0023
Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615. doi: 10.1038/nature10166. DOI: https://doi.org/10.1038/nature10166
Ortega MA, Fraile-Martínez O, García-Montero C. Ovarian cancer—insights into platinum resistance and overcoming it. Medicina (Kaunas). 2023;59(3):544. doi: 10.3390/medicina59030544. DOI: https://doi.org/10.3390/medicina59030544
Patch AM, Christie EL, Etemadmoghadam D. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489-494. doi: 10.1038/nature14410. DOI: https://doi.org/10.1038/nature14410
Galluzzi L, Senovilla L, Vitale I. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869-83. doi: 10.1038/onc.2011.384. DOI: https://doi.org/10.1038/onc.2011.384
Norouzi-Barough L, Sarookhani MR, Sharifi M. Molecular mechanisms of drug resistance in ovarian cancer. J Cell Physiol. 2018;233(6):4546-4562. doi: 10.1002/jcp.26289. DOI: https://doi.org/10.1002/jcp.26289
McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613-628. doi: 10.1016/j.cell.2017.01.018. DOI: https://doi.org/10.1016/j.cell.2017.01.018
Schwarz RF, Ng CKY, Cooke SL. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med. 2015;12(2):e1001789. doi: 10.1371/journal.pmed.1001789. DOI: https://doi.org/10.1371/journal.pmed.1001789
Nasiri F, Safarzadeh Kozani P, Salem F, Mahboubi Kancha M, Dashti Shokoohi S, Safarzadeh Kozani P. Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies. Cancer Cell Int. 2025;25(1):64. doi: 10.1186/s12935-025-03697-y. DOI: https://doi.org/10.1186/s12935-025-03697-y
Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327-344. doi: 10.1038/s41571-021-00470-8. DOI: https://doi.org/10.1038/s41571-021-00470-8
Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21(3):203-223. doi: 10.1038/s41571-023-00850-2. DOI: https://doi.org/10.1038/s41571-023-00850-2
Hao Y, Song Z. Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies. Cancer Drug Resist. 2025;8:59. doi: 10.20517/cdr.2025.148. DOI: https://doi.org/10.20517/cdr.2025.148
Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117(12):1736-1742. doi: 10.1038/bjc.2017.367. DOI: https://doi.org/10.1038/bjc.2017.367
McDermott MS, O'Brien NA, Hoffstrom B, Gong K, Lu M, Zhang J, et al. Preclinical efficacy of the antibody-drug conjugate CLDN6-23-ADC for the treatment of CLDN6-positive solid tumors. Clin Cancer Res. 2023;29(11):2131-243. doi: 10.1158/1078-0432.CCR-22-2981. DOI: https://doi.org/10.1158/1078-0432.CCR-22-2981
Marine J-C, Bartok O, Sagie S, Vitiello PP, Bardelli A, Weller C, et al. Mapping intratumor heterogeneity across layers for advancing immunotherapy. Cell. 2026;189(8):2416-2440. doi: 10.1016/j.cell.2026.03.025. DOI: https://doi.org/10.1016/j.cell.2026.03.025
Zwicke GL, Ali Mansoori G, Jeffery CJ. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 2012;3(1):18496. doi: 10.3402/nano.v3i0.18496. DOI: https://doi.org/10.3402/nano.v3i0.18496
Scaranti M, Cojocaru E, Banerjee S, Banerji U. Exploiting the folate receptor α in oncology. Nat Rev Clin Oncol. 2020;17(6):349-359. doi: 10.1038/s41571-020-0339-5. DOI: https://doi.org/10.1038/s41571-020-0339-5
Kalli KR, Oberg AL, Keeney GL. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108(3):619-626. doi: 10.1016/j.ygyno.2007.11.020. DOI: https://doi.org/10.1016/j.ygyno.2007.11.020
Dilawari A, Shah M, Ison G. FDA approval summary: mirvetuximab soravtansine-gynx. Clin Cancer Res. 2023;29(19):3835-3840. doi: 10.1158/1078-0432.CCR-23-0991. DOI: https://doi.org/10.1158/1078-0432.CCR-23-0991
Kokori E, Olatunji G, Komolafe R, Abraham IC, Ukoaka B, Samuel O, et al. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer. Medicine. 2024;103(20):e38132. doi: 10.1097/MD.0000000000038132. DOI: https://doi.org/10.1097/MD.0000000000038132
Coleman RL, Lorusso D, Oaknin A. Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival from the SORAYA trial. Gynecol Oncol. 2024;186:1-9. doi: 10.1136/ijgc-2024-005401. DOI: https://doi.org/10.1136/ijgc-2024-005401
Moore KN, Angelergues A, Konecny GE. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer (MIRASOL): a phase 3 trial. N Engl J Med. 2023;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. DOI: https://doi.org/10.1056/NEJMoa2309169
Ascione L, Guidi L, Prakash A, Trapani D, LoRusso P, Lou E, et al. Unlocking the potential: biomarkers of response to antibody-drug conjugates. Am Soc Clin Oncol Edu Book. 2024;44(3):e431766. doi: 10.1200/EDBK_431766. DOI: https://doi.org/10.1200/EDBK_431766
Li X, Abrahams C, Embry M. Discovery of STRO-002, a novel homogeneous ADC targeting folate receptor alpha, for the treatment of ovarian and endometrial cancers. Mol Cancer Ther. 2023;22(2):155-167. doi: 10.1158/1535-7163.MCT-22-0322. DOI: https://doi.org/10.1158/1535-7163.MCT-22-0322
Oaknin A, Fariñas-Madrid L, García-Duran C, Martin LP, O'Malley DM, Schilder RJ, et al. Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort. J Clin Oncol. 2024;188:8-16. doi: 10.1200/JCO.2023.41.16_suppl.5508. DOI: https://doi.org/10.1200/JCO.2023.41.16_suppl.5508
Shimizu T, Fujiwara Y, Yonemori K. First-in-human phase 1 study of farletuzumab ecteribulin (MORAb-202), an antibody-drug conjugate targeting folate receptor alpha. Clin Cancer Res. 2021;27(14):3905-3915. doi: 10.1158/1078-0432.CCR-20-4740. DOI: https://doi.org/10.1158/1078-0432.CCR-20-4740
Ab O, Bartle LM, Yoder NC. IMGN151, a next-generation folate receptor alpha-targeting antibody-drug conjugate with a biparatopic design. Mol Cancer Ther. 2024;23(5):667-680.
Reinhard K, Rengstl B, Oehm P. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367(6476):446-453. doi: 10.1126/science.aay5967. DOI: https://doi.org/10.1126/science.aay5967
Hendrickson AW, Konecny GE, Winterhoff B, Adjei AA, Pulaski H, Yoon S, et al. 1074P Claudin- 6 (CLDN6) is a therapeutic target in ovarian cancer (OC): Emerging results from the CATALINA 1 (CAT1) study. Ann Oncol. 2025;36(suppl). doi: 10.1016/j.annonc.2025.08.1713. DOI: https://doi.org/10.1016/j.annonc.2025.08.1714
Kim H, Lee SY, Choi YJ. Claudin-6 expression in primary and recurrent epithelial ovarian cancer: a potential therapeutic target for high-grade serous ovarian cancer. Ann Oncol. 2024;35(suppl 2):S571. doi: 10.1016/j.annonc.2024.08.832. DOI: https://doi.org/10.1016/j.annonc.2024.08.832
Konecny GE, Hamilton EP, Richardson DL. First-in-human phase I study of a novel claudin-6 (CLDN6)-targeted antibody-drug conjugate, TORL-1-23, in advanced solid tumors (CATALINA-1). Ann Oncol. 2023;34(suppl 2):S550. doi: 10.1016/j.annonc.2023.09.193. DOI: https://doi.org/10.1016/j.annonc.2023.09.1935
Du H, Yang X, Fan J, Du X. Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation. Mol Med Rep. 2021;24(3):677. doi: 10.3892/mmr.2021.12316. DOI: https://doi.org/10.3892/mmr.2021.12316
Hamagawa K, Yoshida H, Yagishita S, Shintani D, Yano M, Yasuda M, et al. 71O Profiling antibody-drug conjugate (ADC) target expression in high-grade serous ovarian cancer (HGSOC): opportunities for targeted treatment strategies. ESMO Open. 2025;10. doi: 10.1016/j.esmoop.2025.105200. DOI: https://doi.org/10.1016/j.esmoop.2025.105200
Mackensen A, Haanen JBAG, Koenecke C. CLDN6-specific CAR-T cells plus amplifying RNA vaccine (BNT211) in relapsed or refractory solid tumours: a phase 1 trial. Nat Med. 2023;29(11):2844-53. doi: 10.1038/s41591-023-02612-0. DOI: https://doi.org/10.1038/s41591-023-02612-0
Menon R, Bako E, Liu S, Stec J, Thakur S, Deutschman E, et al. Mirvetuximab soravtansine: mechanism of action, clinical and translational science. Clin Transl Sci. 2026;19(1):e70447. doi: 10.1111/cts.70447. DOI: https://doi.org/10.1111/cts.70447
Nwabufo CK. Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations. Cancer Chemother Pharmacol. 2024;93(2):89-105. doi: 10.1007/s00280-023-04575-y. DOI: https://doi.org/10.1007/s00280-023-04575-y
Yuan R, McGeehan A, Zhou S, Cheng C, Armanini M, Smith J, et al. The anti-FRα antibody–drug conjugate luveltamab tazevibulin demonstrates efficacy in non–small cell lung cancer preclinical models and induces immunogenic cell death. Mol Cancer Ther. 2025;24(9):1428-1441. doi: 10.1158/1535-7163.MCT-24-0649. DOI: https://doi.org/10.1158/1535-7163.MCT-24-0649
Lewis GD. Antibody–drug conjugates: The past, present and future. Ann Rev Cancer Biol. 2025;10. doi: 10.1146/annurev-cancerbio-070524-032954. DOI: https://doi.org/10.1146/annurev-cancerbio-070524-032954
Kim ET, Kim JH, Park EY, Song IH, Park HS, Park SY, et al. The efficacy and safety of folate receptor α‐targeted antibody‐drug conjugate therapy in patients with high‐grade epithelial ovarian, primary peritoneal, or fallopian tube cancers: A systematic review and meta‐analysis. Cancer Med. 2024;13(21):e70392. doi: 10.1002/cam4.70392. DOI: https://doi.org/10.1002/cam4.70392
Niquille DL, Fitzgerald KM, Gera N. Biparatopic antibodies: therapeutic applications and prospects. MAbs. 2024;16(1):2310890. doi: 10.1080/19420862.2024.2310890. DOI: https://doi.org/10.1080/19420862.2024.2310890
Lorenzon I. Chemoresistance in epithelial ovarian cancer: in vitro selection and characterization of platinum resistant cells. Thesis. 2020. Available at: https://air.uniud.it/retrieve/e27ce0c8-8369-055e-e053-6605fe0a7873/Tesi_Lorenzon_Ilaria.pdf
Ogundipe OD, Olajubutu O, Adesina SK. Targeted drug conjugate systems for ovarian cancer chemotherapy. Biomed Pharmacother. 2023;165:115151. doi: 10.1016/j.biopha.2023.115151. DOI: https://doi.org/10.1016/j.biopha.2023.115151
García-Alonso S, Ocaña A, Pandiella A. Resistance to antibody-drug conjugates: an issue of intracellular trafficking. Cancer Res. 2018;78(9):2159-2165. doi: 10.1158/0008-5472.CAN-17-3671. DOI: https://doi.org/10.1158/0008-5472.CAN-17-3671
Loganzo F, Sung M, Gerber HP. Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther. 2016;15(12):2825-2834. doi: 10.1158/1535-7163.MCT-16-0408. DOI: https://doi.org/10.1158/1535-7163.MCT-16-0408
Liu Y, Liu Y, Wu T, Bai X, Wang S, Zhang L, et al. Drug resistance to antibody-drug conjugates: mechanisms, challenges, and perspectives. Cancer Biol Med. 2026. doi: 10.20892/j.issn.2095-3941.2025.0707. DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0707
Vonniessen B, Tabariès S, Siegel PM. Antibody-mediated targeting of Claudins in cancer. Front Oncol. 2024;14:1320766. doi: 10.3389/fonc.2024.1320766. DOI: https://doi.org/10.3389/fonc.2024.1320766
Holm J, Hansen SI. Characterization of soluble folate receptors (folate binding proteins) in humans. Biological roles and clinical potentials in infection and malignancy. Biochim Biophys Acta Proteins Proteom. 2020;1868(10):140466. doi: 10.1016/j.bbapap.2020.140466. DOI: https://doi.org/10.1016/j.bbapap.2020.140466
Azzalini E, Stanta G, Canzonieri V, Bonin S. Overview of tumor heterogeneity in high-grade werous ovarian cancers. Int J Mol Sci. 2023;24(20):15077. doi: 10.3390/ijms242015077. DOI: https://doi.org/10.3390/ijms242015077
Wang WD, Guo YY, Yang ZL, Su GL, Sun ZJ. Sniping cancer stem cells with nanomaterials. ACS Nano. 2023;17(23):23262-23298. doi: 10.1021/acsnano.3c07828. DOI: https://doi.org/10.1021/acsnano.3c07828
Paul S, Konig MF, Pardoll DM, Bettegowda C, Papadopoulos N, Wright KM, et al. Cancer therapy with antibodies. Nat Rev. Cancer. 2024;24(6):399-426. doi: 10.1038/s41568-024-00690-x DOI: https://doi.org/10.1038/s41568-024-00690-x
Screnci B, Stafford LJ, Barnes T, Shema K, Gilman S, Wright R, et al. Antibody specificity against highly conserved membrane protein Claudin 6 driven by single atomic contact point. iScience. 2022;25(12):105665. doi: 10.1016/j.isci.2022.105665. DOI: https://doi.org/10.1016/j.isci.2022.105665
Cheung A, Liu Y, Chenoweth AM, Montaseri H, Esapa B, Chudasama V, et al. Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond. Physiol Rev. 2026;106(3):1681-1756. doi: 10.1152/physrev.00039.2025. DOI: https://doi.org/10.1152/physrev.00039.2025
Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 2016;76(9):2710-2719. doi: 10.1158/0008-5472.CAN-15-1795. DOI: https://doi.org/10.1158/0008-5472.CAN-15-1795
Silverstein J, Karlan B, Herrington N, Konecny G. Antibody–drug conjugates as targeted therapy for treating gynecologic cancers: update 2025. Curr Opin Obstetr Gynecol. 2024;37(1):5. doi: 10.1097/GCO.0000000000000925. DOI: https://doi.org/10.1097/GCO.0000000000001002
Putra AD, Darmawan NS, Rahman AT, Syariatin L. Minimal residual disease detection: Bridging molecular and clinical strategies for recurrence prevention in gynecologic cancers. Int J Mol Sci. 2025;26(23):11708. doi: 10.3390/ijms262311708. DOI: https://doi.org/10.3390/ijms262311708
Shin HG, Yang HR, Yoon A, Lee S. Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy. Int J Mol Sci. 2022;23(10). doi: 10.3390/ijms23105686. DOI: https://doi.org/10.3390/ijms23105686
Feng F, Han X, Fang Z, Xi K, Wang Z, Shen J, et al. Synthetic M13 phage engagers expand CAR-T cell antigen recognition to overcome tumor heterogeneity. Trend Biotechnol. 2026. doi: 10.1016/j.tibtech.2026.02.008. DOI: https://doi.org/10.1016/j.tibtech.2026.02.008
Wang J, Zhang Q, Cao Y, Wang C, Hamzeh S. Precision theranostics in oncology: integrating antibody-drug conjugates, radioimmunotherapy, and immuno‑PET for adaptive cancer care. Discover Oncol. 2026. doi: 10.1007/s12672-026-03124-x DOI: https://doi.org/10.1007/s12672-026-05151-5
Yamazaki CM, Yamaguchi A, Anami Y. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021;12:3528. doi: 10.1038/s41467-021-23793-7. DOI: https://doi.org/10.1038/s41467-021-23793-7
Lorusso D, Ceni V, Daniele G. Newer ADCs and their role in ovarian cancer: the heterogeneity challenge. Ann Oncol. 2023;34(suppl). doi: 10.1016/j.annonc.2023.10.017. DOI: https://doi.org/10.1016/j.annonc.2023.10.017
Scandurra G, Marano F, Gebbia V, Valerio MR, Sambataro D, Lombardo V, et al. Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody–drug conjugates: a narrative review. Clin Transl Oncol. 2026;28(3):746-756. doi: 10.1007/s12094-025-04050-5 DOI: https://doi.org/10.1007/s12094-025-04050-5
Yang M, Huang Y, Qian W, Zhu J, Fei L, Jiao Z, et al. Multifunctional nanotherapeutics for tumor microenvironment modulation in solid tumor therapy. Discover Nano. 2026;21(1):286. doi: 10.1186/s11671-026-04736-x DOI: https://doi.org/10.1186/s11671-026-04736-x
Waseem S, Zhan J, Xiao X, Bai P. Precision oncology in gynecologic cancers: molecular taxonomy, biomarker-guided therapeutics, and the challenge of therapeutic resistance. Front Oncol. 2026;16:1785469. doi: 10.3389/fonc.2026.1785469. DOI: https://doi.org/10.3389/fonc.2026.1785469
Zhou K, Liu X, Zhu H. Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies. J Hematol Oncol. 2025;18(1):96. doi: 10.1186/s13045-025-01752-9. DOI: https://doi.org/10.1186/s13045-025-01752-9
Tew WP, Lacchetti C, Kohn EC. Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38(30):3468-3493. doi: 10.1200/JCO.20.01924. DOI: https://doi.org/10.1200/JCO.20.01924
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Published by Al-Rafidain University College. This is an open access journal issued under the CC BY-NC-SA 4.0 license (https://creativecommons.org/licenses/by-nc-sa/4.0/).
